Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME)

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach